Detalles de la búsqueda
1.
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.
Nephrol Dial Transplant
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38730538
2.
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
Ann Intern Med
; 176(1): 59-66, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36469914
3.
Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 383(15): 1436-1446, 2020 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32970396
4.
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.
Nephrol Dial Transplant
; 38(5): 1260-1270, 2023 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36301617
5.
Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.
Diabetes Obes Metab
; 25(6): 1758-1768, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36843215
6.
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
J Am Soc Nephrol
; 33(11): 2094-2107, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35977807
7.
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
Circulation
; 143(5): 438-448, 2021 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33186054
8.
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Kidney Int
; 101(1): 174-184, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34560136
9.
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Nephrol Dial Transplant
; 37(9): 1647-1656, 2022 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34850160
10.
Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.
Diabetes Obes Metab
; 24(5): 827-837, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984791
11.
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
J Am Soc Nephrol
; 32(9): 2352-2361, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34272327
12.
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Eur Heart J
; 42(13): 1216-1227, 2021 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33792669
13.
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Kidney Int
; 100(1): 215-224, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878338
14.
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Diabetes Obes Metab
; 23(4): 886-896, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33319454
15.
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Nephrol Dial Transplant
; 35(10): 1700-1711, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862232
16.
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
Diabetes Obes Metab
; 22(12): 2493-2498, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32803900
17.
Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
Diabetes Obes Metab
; 22(9): 1556-1566, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32329160
18.
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
Diabetes Obes Metab
; 22(4): 549-556, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31742881
19.
Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial.
J Am Soc Nephrol
; 35(5): 594-606, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38564654
20.
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Cardiovasc Diabetol
; 18(1): 138, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31640705